Chat with us
Research Assistance
Online
  • Please enter your first name.

Middle East & Africa Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Size & Outlook

The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in Middle East & Africa is expected to reach a projected revenue of US$ 500.0 million by 2035. A compound annual growth rate of 4.3% is expected of Middle East & Africa cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market from 2025 to 2035.

  • Clinical Diagnostics
    • Cancer Diagnostics
      • Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook
Revenue, 2024 (US$M)
$316.6
Forecast, 2035 (US$M)
$500.0
CAGR, 2025 - 2035
4.3%
Report Coverage
Middle East & Africa
Prism AI by Grand View ResearchFree to try

Ask a question about the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market

Every figure cited from GVR research

MEA cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market highlights

  • The MEA cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market generated a revenue of USD 316.6 million in 2024.
  • The market is expected to grow at a CAGR of 4.3% from 2025 to 2035.
  • In terms of segment, cervical cancer screening was the largest revenue generating type in 2024.
  • Cervical Cancer Screening is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2025 to 2035.


MEA data book summary

Market revenue in 2024USD 316.6 million
Market revenue in 2035USD 500.0 million
Growth rate4.3% (CAGR from 2025 to 2035)
Largest segmentCervical cancer screening
Fastest growing segmentCervical Cancer Screening
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2035
Quantitative unitsRevenue in USD million
Market segmentationCervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.8% of the global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2035.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 3,288.6 million by 2035.

The Middle East & Africa region, including South Africa, Saudi Arabia, and the UAE, is experiencing growth in the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market due to the high prevalence of the disease. 

In the Middle East and North Africa region, cervical cancer remains a leading cause of female mortality. According to the ICO/IARC HPV Information Centre (2023), deaths are projected to rise from 8,964 in 2012 to 16,241 by 2030, averaging 44 fatalities per day without intervention. 

HPV vaccination, particularly for girls aged 9–13, offers up to 99% efficacy with minimal side effects. However, the financial burden of treating advanced cervical cancer remains a significant challenge for many families, underscoring the need for increased preventive measures and accessible healthcare solutions.

No credit card required*

Publish Date: Apr 15, 2025

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Scope

Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Companies

NameProfile# EmployeesHQWebsite
Roche Holding AG ADRView profile 103,605Grenzacherstrasse 124, Basel, Switzerland, 4070www.roche.com
Abbott LaboratoriesView profile 114,000100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400www.abbottinvestor.com
Becton Dickinson & CoView profile 73,0001 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880www.bd.com
Qiagen NVView profile 5,900Hulsterweg 82, Venlo, LI, Netherlands, 5912 PLwww.qiagen.com
Hologic IncView profile 6,990250 Campus Drive, Marlborough, MA, United States, 01752www.hologic.com
CooperSurgicalView profile 501-1000Trumbull, Connecticut, United States, North Americawww.coopersurgical.com
Utah Medical Products IncView profile 1907043 South 300 West, Midvale, UT, United States, 84047www.utahmed.com
MedGyn ProductsView profile 51-100Addison, Illinois, United States, North Americawww.medgyn.com

Middle East & Africa Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook will help companies and investors design strategic landscapes.


Cervical Cancer Screening was the largest segment with a revenue share of 50.54% in 2024.

Horizon Databook has segmented the Middle East & Africa cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market based on cervical cancer screening, cervical cancer diagnostics, pre-cancerous lesion treatment covering the revenue growth of each sub-segment from 2018 to 2035.




The Middle East & Africa region, including South Africa, Saudi Arabia, and the UAE, is experiencing growth in the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market due to the high prevalence of the disease. 

In the Middle East and North Africa region, cervical cancer remains a leading cause of female mortality. According to the ICO/IARC HPV Information Centre (2023), deaths are projected to rise from 8,964 in 2012 to 16,241 by 2030, averaging 44 fatalities per day without intervention. 

HPV vaccination, particularly for girls aged 9–13, offers up to 99% efficacy with minimal side effects. However, the financial burden of treating advanced cervical cancer remains a significant challenge for many families, underscoring the need for increased preventive measures and accessible healthcare solutions.

  • Middle East & Africa Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Type Outlook (Revenue, USD Million , 2018-2035)
    • Cervical Cancer Screening
    • Cervical Cancer Diagnostics
    • Pre-cancerous Lesion Treatment

Reasons to subscribe to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook

  • Our clientele includes a mix of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook from 2018 to 2035, including revenue numbers, major trends, and company profiles.

Middle East Africa Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market, 2018-2035 (US$M)

No Access Stack Chart

MEA Type - Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Statistics, 2024 - 2035 (US$M)

No Access Pie Chart

MEA cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market statistics, by country, 2018-2035 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more